Major pathogenic effects of anti-MuSK antibodies in Myasthenia Gravis

被引:33
作者
Boneva, Neli
Frenkian-Cuvelier, Melinee
Bidault, Jocelyne
Brenner, Talma
Berrih-Aknin, Sonia
机构
[1] Univ Paris 11, CNRS, UMR 8162, IPSC,Hop Marie Lannelongue, F-92350 Le Plessis Robinson, France
[2] Hadassah Med Ctr, Dept Neurol, IL-91120 Jerusalem, Israel
关键词
MuSK positive myasthenia gravis; muscle atrophy; pathogenic effects; proliferation; gene regulation;
D O I
10.1016/j.jneuroim.2006.05.017
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
MG with anti-MuSK antibodies (MuSK+) is often characterized with muscle atrophy and excellent response to plasma exchanges. To elucidate some MuSK+ MG features, we analyzed the functional effects of anti-MuSK Abs in human TE 671 muscle cells. We found that some MuSK+ sera induced a striking inhibition of proliferation, accompanied by: 1) cell cycle arrest, 2) atrogin-1 overexpression, 3) AChR subunits, rapsyn, Rho A and cdc42 downregulation. These effects correlated to disease severity and to anti-MuSK Abs titer and vanished following PE. Altogether, these results indicate that anti-MuSK Abs could be pathogenic by contributing to the muscle atrophy in MuSK+ MG patients. (c) 2006 Elsevier B.V All rights reserved.
引用
收藏
页码:119 / 131
页数:13
相关论文
共 44 条
[1]   MuSK antibody positive myasthenia gravis plasma modifies MURF-1 expression in C2C12 cultures and mouse muscle in vivo [J].
Benveniste, O ;
Jacobson, L ;
Farrugia, ME ;
Clover, L ;
Vincent, A .
JOURNAL OF NEUROIMMUNOLOGY, 2005, 170 (1-2) :41-48
[2]  
BERRIH S, 1985, J IMMUNOL, V135, P1165
[3]   Akt/mTOR pathway is a crucial regulator of skeletal muscle hypertrophy and can prevent muscle atrophy in vivo [J].
Bodine, SC ;
Stitt, TN ;
Gonzalez, M ;
Kline, WO ;
Stover, GL ;
Bauerlein, R ;
Zlotchenko, E ;
Scrimgeour, A ;
Lawrence, JC ;
Glass, DJ ;
Yancopoulos, GD .
NATURE CELL BIOLOGY, 2001, 3 (11) :1014-1019
[4]   NEUROGENIC MUSCLE ATROPHY IN MYASTHENIA-GRAVIS [J].
BROWNELL, B ;
SPALDING, JM ;
OPPENHEIMER, DR .
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 1972, 35 (03) :311-+
[5]   PASSIVE TRANSFER OF SERONEGATIVE MYASTHENIA-GRAVIS TO MICE [J].
BURGES, J ;
VINCENT, A ;
MOLENAAR, PC ;
NEWSOMDAVIS, J ;
PEERS, C ;
WRAY, D .
MUSCLE & NERVE, 1994, 17 (12) :1393-1400
[6]   The receptor tyrosine kinase MuSK is required for neuromuscular junction formation in vivo [J].
DeChiara, TM ;
Bowen, DC ;
Valenzuela, DM ;
Simmons, MV ;
Poueymirou, WT ;
Thomas, S ;
Kinetz, E ;
Compton, DL ;
Rojas, E ;
Park, JS ;
Smith, C ;
DiStefano, PS ;
Glass, DJ ;
Burden, SJ ;
Yancopoulos, GD .
CELL, 1996, 85 (04) :501-512
[7]   Clinical correlates with anti-MuSK antibodies in generalized seronegative myasthenia gravis [J].
Evoli, A ;
Tonali, PA ;
Padua, L ;
Lo Monaco, M ;
Scuderi, F ;
Batocchi, AP ;
Marino, M ;
Bartoccioni, E .
BRAIN, 2003, 126 :2304-2311
[8]  
FARRUGIA ME, 2006, BRAIN
[9]   Signalling pathways that mediate skeletal muscle hypertrophy and atrophy [J].
Glass, DJ .
NATURE CELL BIOLOGY, 2003, 5 (02) :87-90
[10]   Agrin acts via a MuSK receptor complex [J].
Glass, DJ ;
Bowen, DC ;
Stitt, TN ;
Radziejewski, C ;
Bruno, J ;
Ryan, TE ;
Gies, DR ;
Shah, S ;
Mattsson, K ;
Burden, SJ ;
DiStefano, PS ;
Valenzuela, DM ;
DeChiara, TM ;
Yancopoulos, GD .
CELL, 1996, 85 (04) :513-523